Calcineurin inhibitors and hypertension: a role for pharmacogenetics?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Matas AJ, Smith JM, Skeans MA et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am. J. Transplant. 13(Suppl. 1), 11–46 (2013).
  MedlineGoogle Scholar
• 2 Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. 2(4), 1–23 (2000).
  Medline CASGoogle Scholar
• 3 Jain A, Reyes J, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann. Surg. 230(3), 441–448 (1999).
  Medline CASGoogle Scholar
• 4 Textor SC, Canzanello VJ, Taler SJ et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin. Proc. 69(12), 1182–1193 (1994).
  Medline CASGoogle Scholar
• 5 Canzanello VJ, Textor SC, Taler SJ et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl. Surg. 4(4), 328–334 (1998).
  Medline CASGoogle Scholar
• 6 Opelz G, Dohler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am. J. Transplant. 5(11), 2725–2731 (2005). • Large study on the association between post-transplant hypertension and outcomes.
  MedlineGoogle Scholar
• 7 Kasiske BL, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am. J. Kidney Dis. 43(6), 1071–1081 (2004).
  MedlineGoogle Scholar
• 8 Hesselink DA, Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245–254 (2003).
  Medline CASGoogle Scholar
• 9 Yanagimachi M, Naruto T, Tanoshima R et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin. Transplant. 24(6), 855–861 (2010).
  Medline CASGoogle Scholar
• 10 Naesens M, Lerut E, De Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20(11), 2468–2480 (2009).• Important study that links genetic polymorphism and histological analysis to clinical outcomes.
  MedlineGoogle Scholar
• 11 Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J. Nephrol. 25(3), 269–275 (2012).• Review of the different mechanisms contributing to calcineurin inhibitor (CNI)-induced hypertension.
  Medline CASGoogle Scholar
• 12 Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol. 1(1), 76–83 (1990).
  Medline CASGoogle Scholar
• 13 Textor SC, Burnett JC Jr, Romero JC et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 47(5), 1426–1433 (1995).
  Medline CASGoogle Scholar
• 14 Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506-induced hypertension in the rat. Hypertension 33(1), 130–136 (1999).
  Medline CASGoogle Scholar
• 15 Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J. Clin. Invest. 93(5), 2244–2250 (1994).
  Medline CASGoogle Scholar
• 16 Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 25(4 Pt 2), 764–768 (1995).
  Medline CASGoogle Scholar
• 17 Hoorn EJ, Walsh SB, Unwin RJ, Ellison DH. Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity. J. Hypertens. 30(4), 832–833 (2012).
  Medline CASGoogle Scholar
• 18 Hoorn EJ, Walsh SB, McCormick JA et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat. Med. 17(10), 1304–1309 (2011).• First study showing that tacrolimus activates a sodium transporter in the kidney and that this results in salt-sensitive hypertension.
  Medline CASGoogle Scholar
• 19 Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS. The sodium retaining effects of cyclosporine. Kidney Int. 41(6), 1599–1605 (1992).
  Medline CASGoogle Scholar
• 20 Canzanello VJ, Textor SC, Taler SJ et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. J. Am. Soc. Nephrol. 5(11), 1910–1917 (1995).
  Medline CASGoogle Scholar
• 21 Hadchouel J, Delaloy C, Faure S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J. Am. Soc. Nephrol. 17(1), 208–217 (2006).
  Medline CASGoogle Scholar
• 22 Wilson FH, Disse-Nicodeme S, Choate KA et al. Human hypertension caused by mutations in WNK kinases. Science 293(5532), 1107–1112 (2001).
  Medline CASGoogle Scholar
• 23 Kahle KT, Wilson FH, Leng Q et al. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat. Genet. 35(4), 372–376 (2003).
  Medline CASGoogle Scholar
• 24 Moes AD, Van Der Lubbe N, Zietse R, Loffing J, Hoorn EJ. The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation. Pflugers Arch. 466(1), 107–118 (2014).
  Medline CASGoogle Scholar
• 25 Hoorn EJ, Nelson JH, McCormick JA, Ellison DH. The WNK kinase network regulating sodium, potassium, and blood pressure. J. Am. Soc. Nephrol. 22(4), 605–614 (2011).
  Medline CASGoogle Scholar
• 26 McCormick JA, Mutig K, Nelson JH et al. A SPAK isoform switch modulates renal salt transport and blood pressure. Cell Metab. 14(3), 352–364 (2011).
  Medline CASGoogle Scholar
• 27 Colussi G, Bettinelli A, Tedeschi S et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin. J. Am. Soc. Nephrol. 2(3), 454–460 (2007).
  Medline CASGoogle Scholar
• 28 Melnikov S, Mayan H, Uchida S, Holtzman EJ, Farfel Z. Cyclosporine metabolic side effects: association with the WNK4 system. Eur. J. Clin. Invest. 41(10), 1113–1120 (2011).
  Medline CASGoogle Scholar
• 29 Picard N, Trompf K, Yang CL et al. Protein phosphatase 1 inhibitor-1 deficiency reduces phosphorylation of renal NaCl cotransporter and causes arterial hypotension. J. Am. Soc. Nephrol. 25(3), 511–522 (2013).
  MedlineGoogle Scholar
• 30 Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29(6), 404–430 (1995).
  Medline CASGoogle Scholar
• 31 Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40(3), 159–168 (2001).
  Medline CASGoogle Scholar
• 32 Marks AR. Cellular functions of immunophilins. Physiol. Rev. 76(3), 631–649 (1996).
  Medline CASGoogle Scholar
• 33 Hesselink DA, Bouamar R, Elens L, Van Schaik RH, Van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 53(2), 123–139 (2014).
  Medline CASGoogle Scholar
• 34 Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83(9), 2451–2458 (1994).
  Medline CASGoogle Scholar
• 35 Crettol S, Venetz JP, Fontana M et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics 18(4), 307–315 (2008).
  Medline CASGoogle Scholar
• 36 Vafadari R, Bouamar R, Hesselink DA et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther. Drug Monit. 35(4), 459–465 (2013).
  Medline CASGoogle Scholar
• 37 Capron A, Mourad M, De Meyer M et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 11(5), 703–714 (2010).
  CASGoogle Scholar
• 38 Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51(8), 1374–1381 (2005).
  Medline CASGoogle Scholar
• 39 Dai Y, Iwanaga K, Lin YS et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol. 68(9), 1889–1902 (2004).
  Medline CASGoogle Scholar
• 40 Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574–1583 (2011).
  Medline CASGoogle Scholar
• 41 Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001).•• Important and one of the first studies on polymorphic CYP3A5 expression.
  Medline CASGoogle Scholar
• 42 Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin. Pharmacokinet. 49(4), 207–221 (2010).
  Medline CASGoogle Scholar
• 43 Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet. 49(3), 141–175 (2010).
  Medline CASGoogle Scholar
• 44 Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics 10(3), 477–487 (2009).• Excellent review on the possible roles of CYP3A5 and ABCB1 in hypertension.
  CASGoogle Scholar
• 45 Van Schaik RH, Van Der Heiden IP, Van Den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48(10), 1668–1671 (2002).
  Medline CASGoogle Scholar
• 46 Moller A, Iwasaki K, Kawamura A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 27(6), 633–636 (1999).
  Medline CASGoogle Scholar
• 47 Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA 84(21), 7735–7738 (1987).
  Medline CASGoogle Scholar
• 48 Watlington CO, Kramer LB, Schuetz EG et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am. J. Physiol. 262(6 Pt 2), F927–F931 (1992).
  Medline CASGoogle Scholar
• 49 Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N. Engl. J. Med. 356(19), 1966–1978 (2007).
  Medline CASGoogle Scholar
• 50 Ghosh S, Grogan WM, Basu A, Watlington C. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim. Biophys. Acta 1182(2), 152–156 (1993).
  Medline CASGoogle Scholar
• 51 Givens RC, Lin YS, Dowling AL et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. (1985) 95(3), 1297–1300 (2003).
  Medline CASGoogle Scholar
• 52 Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059–1069 (2004).
  Medline CASGoogle Scholar
• 53 Ho H, Pinto A, Hall SD et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 45(2), 294–298 (2005).
  Medline CASGoogle Scholar
• 54 Bochud M, Eap CB, Elston RC et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J. Hypertens. 24(5), 923–929 (2006).
  Medline CASGoogle Scholar
• 55 Kivistö KT, Niemi M, Schaeffeler E et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am. J. Pharmacogenomics 5(3), 191–195 (2005).
  MedlineGoogle Scholar
• 56 Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE. CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet. Genomics 15(10), 737–741 (2005).
  Medline CASGoogle Scholar
• 57 Kreutz R, Zuurman M, Kain S, Bolbrinker J, De Jong PE, Navis G. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet. Genomics 15(12), 831–837 (2005).
  Medline CASGoogle Scholar
• 58 Langaee TY, Gong Y, Yarandi HN et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin. Pharmacol. Ther. 81(3), 386–391 (2007).
  Medline CASGoogle Scholar
• 59 Lieb W, Bolbrinker J, Doring A et al. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin. Sci. (Lond.) 111(6), 365–372 (2006).
  Medline CASGoogle Scholar
• 60 Zhang L, Miyaki K, Wang W, Muramatsu M. CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J. Hum. Hypertens. 24(5), 345–350 (2010).• Important study that combined genetic data (CYP3A5 polymorphism) with environmental data (salt intake).
  Medline CASGoogle Scholar
• 61 Parker RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J. Cardiovasc. Pharmacol. 47(1), 55–59 (2006).
  Medline CASGoogle Scholar
• 62 Widder JD, Guzik TJ, Mueller CF et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 27(4), 762–768 (2007).
  Medline CASGoogle Scholar
• 63 Eap CB, Bochud M, Elston RC et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 49(5), 1007–1014 (2007).• Similar to [60], important study with focus on gene–environment interaction.
  Medline CASGoogle Scholar
• 64 Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet. Genomics 17(2), 137–144 (2007).
  Medline CASGoogle Scholar
• 65 Liu M, Li Y, Citterio L et al. A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. Am. J. Hypertens. 26(12), 1428–1436 (2013).
  Medline CASGoogle Scholar
• 66 Kreutz R, Zurcher H, Kain S, Martus P, Offermann. G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14(10), 665–671 (2004).
  Medline CASGoogle Scholar
• 67 Ferraresso M, Turolo S, Ghio L et al. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors. Clin. Exp. Hypertens. 33(6), 359–365 (2011).
  Medline CASGoogle Scholar
• 68 Torio A, Auyanet I, Montes-Ares O et al. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. Transplant. Proc. 44(9), 2596–2598 (2012).
  Medline CASGoogle Scholar
• 69 Hoorn EJ, Van Der Lubbe N, Zietse R. The renal WNK kinase pathway: a new link to hypertension. Nephrol. Dial Transplant. 24(4), 1074–1077 (2009).
  Medline CASGoogle Scholar
• 70 Wang Y, O’Connell JR, Mcardle PF et al.From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc. Natl Acad. Sci. USA 106(1), 226–231 (2009).
  Medline CASGoogle Scholar
• 71 Erlich PM, Cui J, Chazaro I et al. Genetic variants of WNK4 in whites and African Americans with hypertension. Hypertension 41(6), 1191–1195 (2003).
  Medline CASGoogle Scholar
• 72 Peng KC, Cluzeaud F, Bens M et al. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J. Histochem. Cytochem. 47(6), 757–768 (1999).
  Medline CASGoogle Scholar
• 73 Arroyo JP, Lagnaz D, Ronzaud C et al. Nedd4-2 modulates renal Na+-Cl- cotransporter via the aldosterone–SGK1–Nedd4–2 pathway. J. Am. Soc. Nephrol. 22(9), 1707–1719 (2011).
  Medline CASGoogle Scholar
• 74 Rao AD, Sun B, Saxena A et al. Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. J. Hum. Hypertens. 27(3), 176–180 (2013).
  Medline CASGoogle Scholar
• 75 Kleinewietfeld M, Manzel A, Titze J et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496(7446), 518–522 (2013).
  Medline CASGoogle Scholar
• 76 Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770–781 (2005).
  Medline CASGoogle Scholar
• 77 Mourer JS, De Koning EJ, Van Zwet EW, Mallat MJ, Rabelink TJ, De Fijter JW. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. Transplantation 96(1), 49–57 (2013).
  Medline CASGoogle Scholar
• 78 Thomas B, Taber DJ, Srinivas TR. Hypertension after kidney transplantation: a pathophysiologic approach. Curr. Hypertens. Rep. 15(5), 458–469 (2013).• Excellent review on all aspects of hypertension after kidney transplantation.
  Medline CASGoogle Scholar
• 79 Chatzikyrkou C, Menne J, Gwinner W et al. Pathogenesis and management of hypertension after kidney transplantation. J. Hypertens. 29(12), 2283–2294 (2011).
  Medline CASGoogle Scholar
• 80 Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst. Rev. (1), CD007893 (2010).
  MedlineGoogle Scholar
• 81 Cross NB, Webster AC, Masson P, O’Connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 88(1), 7–18 (2009).
  Medline CASGoogle Scholar
• 82 Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation 95(6), 889–895 (2013).
  Medline CASGoogle Scholar
• 83 Ibrahim HN, Jackson S, Connaire J et al. Angiotensin II blockade in kidney transplant recipients. J. Am. Soc. Nephrol. 24(2), 320–327 (2013).
  Medline CASGoogle Scholar
• 84 Taber DJ, Srinivas TM, Pilch NA et al. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? Am. J. Nephrol. 38(4), 285–291 (2013).
  Medline CASGoogle Scholar